David J. Straus, Madeleine Duvic, Timothy Kuzel, Steven Horwitz, Marie-France Demierre, Patricia Myskowski and Steven Steckel Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma Cancer 109
Version of Record online: 15 MAR 2007 | DOI: 10.1002/cncr.22596
The efficacy and safety of oral bexarotene alone and then with the addition of subcutaneous interferon alfa-2b was evaluated in patients with cutaneous T-cell lymphoma. The combination was safe. The response rate was similar to that reported with bexarotene alone.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field